FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4318539554> ?p ?o ?g. }

• W4318539554 endingPage "i518" @default.
• W4318539554 startingPage "i517" @default.
• W4318539554 abstract "Abstract Background Recently, a subcutaneous formulation of biosimilar infliximab (CT-P13) (SC-IFX) has been approved for inflammatory bowel disease (IBD). The aims of this study were to evaluate efficacy, safety, pharmacokinetics and patient experience following a switching to SC-IFX in patients who are in clinical remission on IV-IFX maintenance treatment. Methods Multicentre, descriptive, and observational study including Crohn’s disease (CD) and ulcerative colitis (UC) patients who were going to be changed from IV-IFX to SC-IFX on the ENEIDA registry (a large, prospectively maintained database of the Spanish Working Group in IBD–GETECCU). All patients were on clinical and biological remission at least 24 weeks before changing. Demographic and disease data, clinical activity (Harvey-Bradshaw index for CD and mayo index for UC), analytical data (C reactive protein (CRP) and fecal calprotectin (FC), as well as trough levels were collected at baseline, at 12 and 24 weeks. Results One hundred and fifty-five patients were included: 54 UC (35%) and 91 (65%) CD; 44% women and 56% men; age 45.5 years (32-55). IV-IFX was mainly administered due to active disease (72%) and perianal disease (7%) and during 32 months [range 14-56]. Pre-switch, 78 (50.3%) were on 8-weekly dosing of IV-IFX, 77 (49.7%) were with intensification dose and the half (50.3%) were on concomitant immunomodulatory therapy. SC-IFX was mainly switching by COVID-19 pandemic (60%), to increase through levels (15%) or patient request (25%). The majority of patients (140, 90%) remained with standard dose, 8 (5%) required dose intensification (120 mg weekly in 4 and 240 mg every 2 weeks in 4) and 7 (4.5%) had successful de-escalation (120 mg every 3 weeks in 4 and 120 mg every 4 weeks in 3). Clinical indices, CRP levels and FC remained unchanged (Figure). Median SC-IFX levels significantly increased from baseline of 4.5 μg/dl [range 2.6-9.2] to 14 μg/dl [range 9.5-16.2] at week 12 and 13.2 μg/dl [range 10.4-19.7] at week 24. No factors (immunossupresor, body mass index, disease location) were associated with the increase of IFX trough levels. During 24 weeks of follow-up, 16 of the 78 patients (20.5%) stopped immunosuppressant treatment. The adverse events were recorded in 9 patients (5.8%), 4 (2.6%) were hospitalized and 4 (2.6%) had surgery (one of them for perianal disease). Nine patients (5.8%) stopped SC-IFX (1 primary failure, 2 loss of response, 4 adverse events, 1 voluntarily, and 1 surgery). Conclusion The switch from IV to SC IFX maintains clinical remission safely in IBD patients, offers higher drug levels and a good patient acceptance. However, the significance of higher drug levels with SC-IFX requires further exploration." @default.
• W4318539554 created "2023-01-31" @default.
• W4318539554 creator A5000678836 @default.
• W4318539554 creator A5011583406 @default.
• W4318539554 creator A5011756766 @default.
• W4318539554 creator A5017529935 @default.
• W4318539554 creator A5018162344 @default.
• W4318539554 creator A5020148151 @default.
• W4318539554 creator A5021002325 @default.
• W4318539554 creator A5038349365 @default.
• W4318539554 creator A5040213508 @default.
• W4318539554 creator A5043248703 @default.
• W4318539554 creator A5048106956 @default.
• W4318539554 creator A5057330133 @default.
• W4318539554 creator A5073905160 @default.
• W4318539554 creator A5076700702 @default.
• W4318539554 creator A5078153821 @default.
• W4318539554 creator A5079521576 @default.
• W4318539554 creator A5084495381 @default.
• W4318539554 date "2023-01-30" @default.
• W4318539554 modified "2023-10-18" @default.
• W4318539554 title "P383 Real-life experience of the efficacy, safety and pharmacokinetic data of switching from intravenous to subcutaneous infliximab in inactive inflammatory bowel disease patients. Results from the ENEIDA registry" @default.
• W4318539554 doi "https://doi.org/10.1093/ecco-jcc/jjac190.0513" @default.
• W4318539554 hasPublicationYear "2023" @default.
• W4318539554 type Work @default.
• W4318539554 citedByCount "0" @default.
• W4318539554 crossrefType "journal-article" @default.
• W4318539554 hasAuthorship W4318539554A5000678836 @default.
• W4318539554 hasAuthorship W4318539554A5011583406 @default.
• W4318539554 hasAuthorship W4318539554A5011756766 @default.
• W4318539554 hasAuthorship W4318539554A5017529935 @default.
• W4318539554 hasAuthorship W4318539554A5018162344 @default.
• W4318539554 hasAuthorship W4318539554A5020148151 @default.
• W4318539554 hasAuthorship W4318539554A5021002325 @default.
• W4318539554 hasAuthorship W4318539554A5038349365 @default.
• W4318539554 hasAuthorship W4318539554A5040213508 @default.
• W4318539554 hasAuthorship W4318539554A5043248703 @default.
• W4318539554 hasAuthorship W4318539554A5048106956 @default.
• W4318539554 hasAuthorship W4318539554A5057330133 @default.
• W4318539554 hasAuthorship W4318539554A5073905160 @default.
• W4318539554 hasAuthorship W4318539554A5076700702 @default.
• W4318539554 hasAuthorship W4318539554A5078153821 @default.
• W4318539554 hasAuthorship W4318539554A5079521576 @default.
• W4318539554 hasAuthorship W4318539554A5084495381 @default.
• W4318539554 hasBestOaLocation W43185395541 @default.
• W4318539554 hasConcept C112705442 @default.
• W4318539554 hasConcept C126322002 @default.
• W4318539554 hasConcept C141071460 @default.
• W4318539554 hasConcept C2777138892 @default.
• W4318539554 hasConcept C2777288759 @default.
• W4318539554 hasConcept C2778260677 @default.
• W4318539554 hasConcept C2778292693 @default.
• W4318539554 hasConcept C2779008522 @default.
• W4318539554 hasConcept C2779134260 @default.
• W4318539554 hasConcept C2779280984 @default.
• W4318539554 hasConcept C2779384505 @default.
• W4318539554 hasConcept C2780132546 @default.
• W4318539554 hasConcept C2780479503 @default.
• W4318539554 hasConcept C59491497 @default.
• W4318539554 hasConcept C71924100 @default.
• W4318539554 hasConcept C90924648 @default.
• W4318539554 hasConceptScore W4318539554C112705442 @default.
• W4318539554 hasConceptScore W4318539554C126322002 @default.
• W4318539554 hasConceptScore W4318539554C141071460 @default.
• W4318539554 hasConceptScore W4318539554C2777138892 @default.
• W4318539554 hasConceptScore W4318539554C2777288759 @default.
• W4318539554 hasConceptScore W4318539554C2778260677 @default.
• W4318539554 hasConceptScore W4318539554C2778292693 @default.
• W4318539554 hasConceptScore W4318539554C2779008522 @default.
• W4318539554 hasConceptScore W4318539554C2779134260 @default.
• W4318539554 hasConceptScore W4318539554C2779280984 @default.
• W4318539554 hasConceptScore W4318539554C2779384505 @default.
• W4318539554 hasConceptScore W4318539554C2780132546 @default.
• W4318539554 hasConceptScore W4318539554C2780479503 @default.
• W4318539554 hasConceptScore W4318539554C59491497 @default.
• W4318539554 hasConceptScore W4318539554C71924100 @default.
• W4318539554 hasConceptScore W4318539554C90924648 @default.
• W4318539554 hasIssue "Supplement_1" @default.
• W4318539554 hasLocation W43185395541 @default.
• W4318539554 hasOpenAccess W4318539554 @default.
• W4318539554 hasPrimaryLocation W43185395541 @default.
• W4318539554 hasRelatedWork W1556902742 @default.
• W4318539554 hasRelatedWork W2161661686 @default.
• W4318539554 hasRelatedWork W2340346586 @default.
• W4318539554 hasRelatedWork W2693060762 @default.
• W4318539554 hasRelatedWork W2791878010 @default.
• W4318539554 hasRelatedWork W2999425959 @default.
• W4318539554 hasRelatedWork W3097733214 @default.
• W4318539554 hasRelatedWork W3210943096 @default.
• W4318539554 hasRelatedWork W4207051201 @default.
• W4318539554 hasRelatedWork W4236271244 @default.
• W4318539554 hasVolume "17" @default.
• W4318539554 isParatext "false" @default.
• W4318539554 isRetracted "false" @default.
• W4318539554 workType "article" @default.